Third Party Pharmacogenomic Products Sample Clauses

Third Party Pharmacogenomic Products. To the extent that BD obtains rights that it can sublicense in accordance with the BD/MPI Collaboration Agreement and that it can sublicense in a manner commensurate in scope with the grant of Section 2.1(b)(vi), BD shall grant to each of Newco and TriPath sublicense rights for Third Party Pharmacogenomic Products that are commensurate in scope, to the extent possible in view of BD's license rights from MPI, with the sublicense rights granted in Section 2.1(b)(vi). --------------- CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.
Sample 1
AutoNDA by SimpleDocs
Third Party Pharmacogenomic Products. With respect to each sale of each Third Party Pharmacogenomic Product by Newco or TriPath, Newco or TriPath, as the case may be, shall pay to BD a royalty [*****].
Sample 1
Third Party Pharmacogenomic Products. With respect to each sale of each Third Party Pharmacogenomic Product by Becton Dickxxxxx, xxs Affiliates or Approved Sublicensees, Becton Dickxxxxx xxxll pay to MPMx a royalty of (i) [**] Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. on such Third Party Pharmacogenomic Product if MPMx has retained, and has licensed to Becton Dickxxxxx, xxclusive rights to commercialize such Third Party Pharmacogenomic Product, or (ii) [**] on such Third Party Pharmacogenomic Product if MPMx has retained, and has licensed to Becton Dickxxxxx, xxn-exclusive rights to commercialize such Third Party Pharmacogenomic Product.
Sample 1
Third Party Pharmacogenomic Products. To the extent that BD grants sublicense rights to Newco and TriPath pursuant to Section 2.1(c) of the Newco Sublicense Agreement, BD shall grant, and does hereby grant, license rights to each of Newco and TriPath under Becton Dicxxxxxx Xxtellectual Property for Third Party Pharmacogenomic Products that are commensurate in scope with the sublicense rights granted pursuant to Section 2.1(c) of the Newco Sublicense Agreement. Such license rights shall be specified in an amendment to this Agreement (including without limitation an appropriate amendment to Section 4.2) to be prepared and executed promptly following BD's obtainment of commercialization rights relating to Third Party Pharmacogenomic Products in accordance with the BD/MPI Collaboration Agreement.
Sample 1
Third Party Pharmacogenomic Products. To the extent that BD grants sublicense rights to Newco and TriPath pursuant to Section 2.1(c) of the Newco Sublicense Agreement, TriPath shall grant, and does hereby grant, (i) to Newco license rights under TriPath Program Intellectual Property for Third Party Pharmacogenomic Products that are commensurate in scope with the sublicense rights granted pursuant to Section 2.1(c) of the Newco Sublicense Agreement, and (ii) to BD license rights under TriPath Program Intellectual Property for Third Party Pharmacogenomic Products that are commensurate in scope with the rights retained by BD from the grant of Section 2.1(c) of the Newco Sublicense Agreement. Such license rights shall be specified in an amendment to this Agreement to be prepared and executed promptly following BD's obtainment of commercialization rights relating to Third Party Pharmacogenomic Products in accordance with the BD/MPI Collaboration Agreement.
Sample 1

Related to Third Party Pharmacogenomic Products

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Product The term “

  • Competing Products The provisions of Section 21 are set forth on attached Exhibit H and are incorporated in this Section 21 by this reference.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Sublicensee The term “Sublicensee” shall mean any third party to whom Licensee grants a sublicense or similar rights with respect to the rights conferred upon Licensee under this Agreement, as contemplated by Section 2.3. In addition, “Sublicensee” shall include any and all further third party Sublicensees that may be permitted under Section 2.3.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Sublicensees Licensee shall have the full right (but not the obligation) to sublicense those rights granted to it under Section 2.1 to a Third Party (a “Sublicensee”); provided, however, that, prior to the payment of the first milestone pursuant to Section 7.2, Licensee may not grant any such sublicense to any contract research organization conducting Clinical Trials of Products or any Third Parties conducting contract Manufacturing activities without Licensee’s prior written notice (at least twenty (20) Business Days in advance) to Lilly, which shall include a description of the rights to be granted and the purpose therefor, the identity of the Third Party and the countries involved, and Lilly’s prior written consent, but such consent shall only be required (i) until such time as Licensee is the holder of record for the Regulatory Materials related to Taladegib and (ii) to the extent such organization is not performing services for Licensee as of the Effective Date; and provided further, that Licensee shall remain responsible for the performance by any of its Sublicensees. With respect to any Sublicensee granted a sublicense to any Commercialization rights hereunder, Licensee shall ensure that each of its Sublicensees accepts in writing all applicable terms and conditions of this Agreement, including the non-compete, reporting, audit, inspection and confidentiality provisions hereunder. Each Sublicensee shall also be prohibited from further sublicensing. For the avoidance of doubt, (a) Licensee will remain directly responsible for all amounts owed to Lilly under this Agreement, and (b) each Sublicensee is subject to the negative and restrictive covenants set forth in Sections 2.3.1 and 2.5, respectively. Licensee hereby expressly waives any requirement that Lilly exhaust any right, power or remedy, or proceed against a subcontractor, for any obligation or performance hereunder prior to proceeding directly against Licensee.

  • Third Party Technology The assignment of any applicable license agreements with respect to Third Party Technology are set forth in the General Assignment and Assumption Agreement.

  • Licensed Territory Worldwide NIH Patent License Agreement—Exclusive APPENDIX C – ROYALTIES Royalties:

Time is Money Join Law Insider Premium to draft better contracts faster.